Table 3.
Change in cardiometabolic risk factors per SD increase in visceral fat, visceral adipose tissue/total body fat ratio, total body fat, and lean body mass
| Trans women (n = 179) | Trans men (n = 162) | |||||||
|---|---|---|---|---|---|---|---|---|
| Visceral fat | VAT/TBF | Total body fat | Lean body mass | Visceral fat | VAT/TBF | Total body fat | Lean body mass | |
| (SD 87 g) | (SD 0.25%) | (SD 4468 g) | (SD 2832 g) | (SD 83 g) | (SD 0.23%) | (SD 4333 g) | (SD 2721 g) | |
| Total cholesterol (mmol/L) | 0.27 (0.17, 0.36) | 0.02 (−0.08, 0.13) | 0.28 (0.18, 0.37) | 0.16 (0.06, 0.26) | 0.04 (−0.07, 0.15) | 0.01 (−0.10, 0.12) | 0.08 (−0.03, 0.18) | 0.02 (−0.09, 0.12) |
| Adjusted | 0.16 (0.04, 0.27) | 0.06 (−0.04, 0.16) | 0.17 (0.03, 0.30) | 0.03 (−0.09, 0.14) | −0.01 (−0.15, 0.13) | 0.02 (−0.10, 0.13) | 0.09 (−0.06, 0.23) | −0.01 (−0.12, 0.11) |
| HDL-cholesterol (mmol/L) | −0.03 (−0.07, 0.01) | 0.02 (−0.02, 0.05) | −0.03 (−0.07, 0.00) | −0.03 (−0.07, 0.00) | −0.01 (−0.07, 0.05) | 0.00 (−0.06, 0.06) | −0.02 (−0.07, 0.04) | −0.03 (−0.08, 0.03) |
| Adjusted | −0.02 (−0.07, 0.02) | 0.01 (−0.03, 0.05) | −0.01 (−0.06, 0.04) | −0.02 (−0.07, 0.02) | −0.00 (−0.07, 0.07) | −0.00 (−0.06, 0.05) | −0.01 (−0.09, 0.06) | −0.02 (−0.08, 0.04) |
| LDL-cholesterol (mmol/L) | 0.23 (0.15, 0.31) | −0.02 (−0.10, 0.01) | 0.24 (0.16, 0.32) | 0.16 (0.08, 0.24) | −0.02 (−0.13, 0.09) | −0.02 (−0.13, 0.09) | 0.05 (−0.05, 0.16) | −0.02 (−0.13, 0.08) |
| Adjusted | 0.13 (0.04, 0.23) | 0.02 (−0.07, 0.10) | 0.13 (0.02, 0.24) | 0.05 (−0.04, 0.14) | −0.09 (−0.23, 0.05) | −0.03 (−0.14, 0.09) | 0.12 (−0.02, 0.26) | −0.05 (−0.16, 0.06) |
| Triglycerides (mmol/L) | 0.16 (0.08, 0.25) | 0.05 (−0.04, 0.13) | 0.16 (0.08, 0.24) | 0.08 (−0.00, 0.16) | 0.07 (−0.03, 0.17) | −0.00 (−0.10, 0.10) | 0.06 (−0.03, 0.16) | 0.08 (−0.02, 0.17) |
| Adjusted | 0.11 (0.00, 0.21) | 0.07 (−0.02, 0.15) | 0.09 (−0.02, 0.21) | 0.00 (−0.10, 0.10) | 0.05 (−0.08, 0.17) | −0.00 (−0.10, 0.11) | 0.01 (−0.11, 0.14) | 0.07 (−0.04, 0.17) |
| HOMA-IRa | 0.13 (−0.22, 0.49) | −0.37(−0.68, −0.05) | 0.67 (0.26, 1.08) | 0.42 (0.07, 0.78) | 0.18 (−0.13, 0.50) | 0.02 (−0.30, 0.35) | 0.19 (−0.17, 0.56) | 0.32 (−0.06, 0.70) |
| Adjusted | −0.20 (−0.60, 0.20) | −0.29 (−0.62, 0.02) | 0.72 (0.12, 1.32) | 0.10 (−0.34, 0.55) | 0.11 (−0.27, 0.50) | 0.05 (−0.27, 0.38) | 0.07 (−0.38, 0.52) | 0.30 (−0.11, 0.70) |
Data are expressed as mean change in risk factor with 95% CI per SD of measure of body fat or lean body mass. Adjusted: analyses between change in visceral fat and risk factors were adjusted for changes in total body fat and lean body mass. Analyses between change in VAT/TBF and risk factors were adjusted for change in lean body mass. Analyses on total body fat were adjusted for visceral fat and lean body mass. Analyses on lean body mass were adjusted for visceral fat and total body fat.
Abbreviations: HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; LDL, low-density lipoprotein; VAT/TBF, visceral adipose tissue/total body fat ratio.
a Eight trans women and 6 trans men were excluded from the specific analysis for having diabetes mellitus.